Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, multicenter, randomized, two-armed, double-blind, parallel, active-controlled, non-inferiority clinical trial to compare efficacy and safety of test-Aflibercept (CinnaGen Co, Iran) to the reference Aflibercept product (Eylea, Regeneron, USA) in patients with Neovascular age-related macular degeneration

Next Previous
Trial Profile

A Phase III, multicenter, randomized, two-armed, double-blind, parallel, active-controlled, non-inferiority clinical trial to compare efficacy and safety of test-Aflibercept (CinnaGen Co, Iran) to the reference Aflibercept product (Eylea, Regeneron, USA) in patients with Neovascular age-related macular degeneration

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors CinnaGen

Most Recent Events

  • 16 Oct 2022 Status changed from active, no longer recruiting to completed.
  • 30 Nov 2020 Status changed from recruiting to active, no longer recruiting.
  • 24 Sep 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top